In August, the clinical review of 3 blockbuster new drugs CDE was completed
-
Last Update: 2016-08-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Amxetine hydrochloride enteric coated tablet is a new SNRIs (5-HT and NE reuptake inhibitor) candidate drug, which is mainly used in antidepressant treatment This product was applied for clinical application in January 2016 It was jointly applied by Sinopharm and Academy of Military Sciences of Shiyao group It is a special approved product and has been reviewed Xinda biological PD-1 antibody ibi308 has been reviewed This product is used in tumor immunotherapy and has the potential to be used in lung cancer, non-Hodgkin lymphoma and other high-risk tumors Xinda is committed to building it into the best in class with the same target drug At present, the right license of this product outside China has been given to Lilly, an international pharmaceutical giant This product entered CDE in January 2016 and has been reviewed Shr-a1201 for injection is an anti-tumor antibody drug conjugate (ADCs) declared by Hengrui in 2013 It was approved in March 2016 and has been reviewed after a supplement.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
